<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-038976</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effect of atorvastatin on plasma fibrinogen levels in patients with type 2 diabetes mellitus and dyslipidemia</dc:title>
<dc:description xml:lang="en">Introduction Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease. Prospective studies indicate that fibrinogen levels are associated with an increased risk for cardiovascular events. Therefore, we tested the effect of atorvastatin on fibrinogen levels in patients with type 2 diabetes mellitus. Patients and methods Fibrinogen was evaluated at baseline and after 6 months of therapy with 20 mg atorvastatin daily in 45 non-smoking patients with type 2 diabetes mellitus and hyperlipidemia. Clinical and biochemical data were obtained. Results Fibrinogen levels were significantly decreased after treatment with atorvastatin compared with baseline (mean change: ­0.60 g/L; p &lt; 0.001). A correlation between baseline fibrinogen levels and microalbuminuria was found (r = 0.349; p &lt; 0.05). Fibrinogen reduction was significantly correlated with baseline fibrinogen levels (r = 0.407, p &lt; 0.05) and baseline glycosylated hemoglobin values (r = 0.369, p &lt; 0.05). Conversely, no significant correlation was found between fibrinogen reduction and change in low-density lipoprotein (LDL)-cholesterol. Conclusion Plasma fibrinogen levels decreased in patients with type 2 diabetes and hyperlipidemia treated with atorvastatin. This decrease was largely independent of LDL-cholesterol reduction (AU)</dc:description>
<dc:creator>Alcaraz, M. S</dc:creator>
<dc:creator>Carrillo, A</dc:creator>
<dc:creator>Orea, I</dc:creator>
<dc:creator>Illán, F</dc:creator>
<dc:creator>Pascual, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción La diabetes mellitus tipo 2 se asocia con un aumento de riesgo de enfermedad cardiovascular. Estudios prospectivos indican que valores elevados de fibrinógeno se relacionan con mayor riesgo de episodios cardiovasculares. Por este motivo, se ha examinado el efecto del tratamiento de la hiperlipemia con atorvastatina sobre el valor del fibrinógeno en pacientes con diabetes mellitus tipo 2. Pacientes y métodos Se ha evaluado el fibrinógeno basal y tras 6 meses de tratamiento con 20 mg al día de atorvastatina en 45 pacientes con diabetes mellitus tipo 2 no fumadores con hiperlipemia. Se obtuvieron datos clínicos y analíticos. Resultados Los valores de fibrinógeno disminuyeron significativamente tras tratamiento con atorvastatina (media = ­0,60 g/l; p &lt; 0,001). Se observa una correlación entre los valores basales de fibrinógeno y microalbuminuria (r = 0,349; p &lt; 0,05). La reducción del fibrinógeno se correlacionó de forma significativa con los valores basales de fibrinógeno (r = 0,407; p &lt; 0,05) y la hemoglobina glucosilada basal (r = 0,369; p &lt; 0,05) pero no se relacionó con la disminución del colesterol ligado a lipoproteínas de baja densidad (cLDL). Conclusión Hemos comprobado una disminución de las concentraciones plasmáticas de fibrinógeno en diabéticos tipo 2 con dislipemia tras tratamiento con atorvastatina, que es independiente de la reducción del cLDL. Effect of atorvastatin on plasma fibrinogen levels in patients with type 2 diabetes mellitus and dyslipidemia (AU)</dc:description>
<dc:source>Endocrinol Nutr;52(7): 333-337, ago. 2005. tab</dc:source>
<dc:identifier>ibc-038976</dc:identifier>
<dc:title xml:lang="es">Efecto de atorvastatina sobre los valores de fibrinógeno en pacientes con diabetes mellitus tipo y 2 dislipemia</dc:title>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d1812^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d931^s22079</dc:subject>
<dc:subject>^d7130^s22057</dc:subject>
<dc:subject>^d22179^s22020</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d2834^s22062</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d422</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200508</dc:date>
</metadata>
</record>
</ibecs-document>
